Zealand Pharma (CPSE:ZEAL) Reports Weaker Earnings, Is It Still Below Fair Value?
Zealand Pharma (CPSE:ZEAL) is back in focus after its second quarter 2026 earnings, which showed lower sales and net income compared with the same periods in 2025 and prompted investors to reassess the stock.
At a share price of DKK317.0, Zealand Pharma has seen modest recent momentum, with a 1 month share price return of 3.63% and a small gain over 7 days. The year to date share price return is down 31.10% and the 1 year total shareholder return is down 28.18%. However, the 3 and 5 year total shareholder returns of 23.44% and 52.26% point to a stronger longer term picture despite the reset in expectations following weaker 2026 earnings.
Spot fresh ideas alongside Zealand Pharma by reviewing the curated 611 high quality undiscovered gems that have flown under the radar despite solid fundamentals.Zealand Pharma now trades at a sizeable discount to consensus targets after a sharp reset in expectations following the weaker 2026 earnings. This raises the question of whether that gap hints at undue caution or reflects real concern about the earnings profile.
Most Popular Narrative: 30.7% Undervalued
At a last close of DKK317.0 compared with a narrative fair value of DKK457.57, Zealand Pharma is framed as materially undervalued in the most widely followed storyline, which leans heavily on its obesity pipeline and partnership structure.
The analysts have a consensus price target of DKK457.57 for Zealand Pharma based on their expectations of its future earnings growth, profit margins and other risk factors.
However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of DKK745.0, and the most bearish reporting a price target of just DKK300.0.
Want to understand why this narrative still arrives at a much higher fair value even with forecast revenue and earnings declines baked in? The key is how margins, future profitability and valuation multiples are stitched together around those obesity assets. Curious which assumptions have to hold for that projected value to make sense.
Result: Fair Value of DKK457.57 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, there is still meaningful downside risk to this Zealand Pharma narrative if key obesity trials disappoint or if partners like Roche and Boehringer Ingelheim slow execution.
Find out about the key risks to this Zealand Pharma narrative.
Next Steps
With sentiment clearly split on Zealand Pharma after the recent earnings reset, it may be helpful to review the data directly using the 1 key reward and 2 important warning signs.
Looking for more investment ideas beyond Zealand Pharma?
If Zealand Pharma has sharpened your focus on opportunities, now is the time to widen your watchlist and pressure test your next moves using clear, data driven stock ideas.
- Explore potential upside with companies that our filters flag as quality opportunities trading at a discount by reviewing the 267 high quality undervalued stocks.
- Focus on your income stream by reviewing businesses with higher yields that still clear fundamental checks through the 414 dividend fortresses.
- Manage portfolio risk by concentrating on companies that screen well for resilience and lower risk profiles using the 299 resilient stocks with low risk scores.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com